Fidelity Investments
IHE icon

Fidelity Investments’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Fidelity Investments’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Buy
19,814
+5,022
+34% +$440K ﹤0.01% 2691
2025
Q4 		$1.25M Buy
14,792
+1,890
+15% +$151K ﹤0.01% 2766
2025
Q3 		$936K Buy
12,902
+1,005
+8% +$69.3K ﹤0.01% 2814
2025
Q2 		$780K Sell
11,897
-206
-2% -$13.4K ﹤0.01% 2806
2025
Q1 		$854K Sell
12,103
-1,222
-9% -$84.9K ﹤0.01% 2729
2024
Q4 		$876K Sell
13,325
-256
-2% -$17.6K ﹤0.01% 2716
2024
Q3 		$959K Buy
13,581
+1,338
+11% +$93.2K ﹤0.01% 2613
2024
Q2 		$812K Buy
12,243
+2,117
+21% +$139K ﹤0.01% 2586
2024
Q1 		$687K Buy
10,126
+3,265
+48% +$216K ﹤0.01% 2620
2023
Q4 		$424K Buy
6,861
+2,451
+56% +$144K ﹤0.01% 2729
2023
Q3 		$260K Sell
4,410
-477
-10% -$29.3K ﹤0.01% 2805
2023
Q2 		$292K Sell
4,887
-741
-13% -$44.1K ﹤0.01% 2832
2023
Q1 		$329K Buy
5,628
+294
+6% +$17.7K ﹤0.01% 2828
2022
Q4 		$331K Sell
5,334
-1,446
-21% -$87K ﹤0.01% 2856
2022
Q3 		$383K Buy
6,780
+543
+9% +$33.4K ﹤0.01% 2862
2022
Q2 		$398K Buy
6,237
+378
+6% +$24K ﹤0.01% 2914
2022
Q1 		$379K Buy
5,859
+540
+10% +$34.2K ﹤0.01% 3072
2021
Q4 		$354K Buy
5,319
+540
+11% +$34.2K ﹤0.01% 2854
2021
Q3 		$291K Hold
4,779
– – ﹤0.01% 2889
2021
Q2 		$295K Sell
4,779
-192
-4% -$11.7K ﹤0.01% 2868
2021
Q1 		$295K Sell
4,971
-204
-4% -$12.3K ﹤0.01% 2764
2020
Q4 		$309K Sell
5,175
-645
-11% -$36.8K ﹤0.01% 2730
2020
Q3 		$317K Sell
5,820
-24
-0.4% -$1.29K ﹤0.01% 2618
2020
Q2 		$300K Sell
5,844
-123
-2% -$6.18K ﹤0.01% 2559
2020
Q1 		$268K Buy
5,967
+1,479
+33% +$74.6K ﹤0.01% 2530
2019
Q4 		$239K Buy
4,488
+1,635
+57% +$80.6K ﹤0.01% 2605
2019
Q3 		$133K Sell
2,853
-1,233
-30% -$59K ﹤0.01% 2703
2019
Q2 		$205K Buy
4,086
+18
+0.4% +$890 ﹤0.01% 2634
2019
Q1 		$209K Sell
4,068
-69
-2% -$3.43K ﹤0.01% 2582
2018
Q4 		$194K Sell
4,137
-534
-11% -$27.4K ﹤0.01% 2558
2018
Q3 		$261K Buy
+4,671
New +$255K ﹤0.01% 2614
2013
Q3 		– Sell
-296,067
Closed -$9.83M – 2641
2013
Q2 		$9.83M Buy
+296,067
New +$9.84M ﹤0.01% 1934

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Fidelity Investments's IHE Position: Q1 2026 in Review

Fidelity Investments increased its iShares US Pharmaceuticals ETF (IHE) stake by 34% in Q1 2026, buying an estimated $440K and bringing the position to 19,814 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2691.

Fidelity Investments first reported a position in IHE in Q2 2013 and has held it in 32 quarters since. The position peaked at $9.83M in Q2 2013. 194 funds tracked by Wall St. Rank hold IHE as of Q1 2026.

  • Fidelity Investments held 19,814 shares of iShares US Pharmaceuticals ETF worth $1.72M as of Q1 2026.
  • Fidelity Investments bought 5,022 iShares US Pharmaceuticals ETF shares in Q1 2026, an estimated $440K.
  • iShares US Pharmaceuticals ETF made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2691 holding.
  • Fidelity Investments first reported a position in iShares US Pharmaceuticals ETF in Q2 2013 and has held it in 32 quarters since.
  • Fidelity Investments's iShares US Pharmaceuticals ETF position peaked at $9.83M in Q2 2013.
  • 194 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.